CTKB – Cytek Biosciences, Inc.
CTKB — Price & Forward EBITDA
Forward EBITDA (M)
Float Short %
6.49
Margin Of Safety %
Put/Call OI Ratio
0.08
EPS Next Q Diff
EPS Last/This Y
0.43
EPS This/Next Y
0.13
Price
4.32
Target Price
6
Analyst Recom
2.2
Performance Q
-14.79
Upside
-521.3%
Beta
1.24
Ticker: CTKB
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-02-27 | CTKB | 4.49 | 0.04 | 0.20 | 1468 |
| 2026-03-02 | CTKB | 4.43 | 0.04 | 0.20 | 1468 |
| 2026-03-03 | CTKB | 4.43 | 0.04 | 30.00 | 1474 |
| 2026-03-04 | CTKB | 4.42 | 0.13 | 999.99 | 1596 |
| 2026-03-05 | CTKB | 4.38 | 0.14 | 0.00 | 1616 |
| 2026-03-06 | CTKB | 4.23 | 0.14 | 0.00 | 1615 |
| 2026-03-09 | CTKB | 4.36 | 0.14 | 0.00 | 1615 |
| 2026-03-10 | CTKB | 4.22 | 0.14 | 0.00 | 1614 |
| 2026-03-11 | CTKB | 4.17 | 0.14 | 10.00 | 1612 |
| 2026-03-12 | CTKB | 3.99 | 0.14 | 10.00 | 1612 |
| 2026-03-13 | CTKB | 4 | 0.14 | 10.00 | 1612 |
| 2026-03-17 | CTKB | 4.26 | 0.15 | 999.99 | 1637 |
| 2026-03-18 | CTKB | 4.34 | 0.15 | 999.99 | 1637 |
| 2026-03-19 | CTKB | 4.52 | 0.16 | 1.82 | 1647 |
| 2026-03-20 | CTKB | 4.49 | 0.18 | 0.00 | 1670 |
| 2026-03-23 | CTKB | 4.72 | 0.04 | 5.00 | 1451 |
| 2026-03-24 | CTKB | 4.64 | 0.06 | 999.99 | 1472 |
| 2026-03-25 | CTKB | 4.61 | 0.06 | 999.99 | 1472 |
| 2026-03-26 | CTKB | 4.59 | 0.08 | 0.00 | 1502 |
| 2026-03-27 | CTKB | 4.32 | 0.08 | 20.00 | 1505 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-02-27 | CTKB | 4.49 | -87.0 | - | 0.01 |
| 2026-03-02 | CTKB | 4.44 | -87.0 | - | 0.01 |
| 2026-03-03 | CTKB | 4.43 | -87.0 | - | 0.01 |
| 2026-03-04 | CTKB | 4.42 | -87.0 | - | 0.01 |
| 2026-03-05 | CTKB | 4.38 | -87.0 | - | 0.01 |
| 2026-03-06 | CTKB | 4.22 | -87.0 | - | 0.01 |
| 2026-03-09 | CTKB | 4.36 | -139.0 | - | -0.09 |
| 2026-03-10 | CTKB | 4.23 | -139.0 | - | -0.09 |
| 2026-03-11 | CTKB | 4.16 | -139.0 | - | -0.09 |
| 2026-03-12 | CTKB | 3.99 | -139.0 | - | -0.09 |
| 2026-03-13 | CTKB | 4.01 | -139.0 | - | -0.09 |
| 2026-03-17 | CTKB | 4.25 | -139.0 | - | -0.09 |
| 2026-03-18 | CTKB | 4.35 | -139.0 | - | -0.09 |
| 2026-03-19 | CTKB | 4.52 | -139.0 | - | -0.09 |
| 2026-03-20 | CTKB | 4.48 | -139.0 | - | -0.09 |
| 2026-03-23 | CTKB | 4.72 | -139.0 | - | -0.09 |
| 2026-03-24 | CTKB | 4.64 | -139.0 | - | -0.09 |
| 2026-03-25 | CTKB | 4.61 | -139.0 | - | -0.09 |
| 2026-03-26 | CTKB | 4.58 | -139.0 | - | -0.09 |
| 2026-03-27 | CTKB | 4.32 | -139.0 | - | -0.09 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-02-27 | CTKB | 0.00 | 0.59 | 5.78 |
| 2026-03-02 | CTKB | 0.00 | 1.30 | 5.75 |
| 2026-03-03 | CTKB | 0.00 | 1.30 | 5.75 |
| 2026-03-04 | CTKB | 0.00 | 1.30 | 5.75 |
| 2026-03-05 | CTKB | 0.00 | 1.30 | 5.75 |
| 2026-03-06 | CTKB | 0.00 | 1.30 | 5.75 |
| 2026-03-09 | CTKB | 0.00 | 1.31 | 5.75 |
| 2026-03-10 | CTKB | 0.00 | 1.31 | 5.75 |
| 2026-03-11 | CTKB | 0.00 | 1.31 | 6.25 |
| 2026-03-12 | CTKB | 0.00 | 1.31 | 6.25 |
| 2026-03-13 | CTKB | 0.00 | 1.31 | 6.25 |
| 2026-03-17 | CTKB | 0.00 | 1.33 | 6.25 |
| 2026-03-18 | CTKB | 0.00 | 1.33 | 6.25 |
| 2026-03-19 | CTKB | 0.00 | 1.33 | 6.25 |
| 2026-03-20 | CTKB | 0.00 | 1.33 | 6.25 |
| 2026-03-23 | CTKB | 0.00 | 1.31 | 6.25 |
| 2026-03-24 | CTKB | 0.00 | 1.31 | 6.25 |
| 2026-03-25 | CTKB | 0.00 | 1.31 | 6.49 |
| 2026-03-26 | CTKB | 0.00 | 1.31 | 6.49 |
| 2026-03-27 | CTKB | 0.00 | 1.31 | 6.49 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.04
Avg. EPS Est. Current Quarter
-0.07
Avg. EPS Est. Next Quarter
-0.04
Insider Transactions
Institutional Transactions
1.31
Beta
1.24
Average Sales Estimate Current Quarter
43
Average Sales Estimate Next Quarter
48
Fair Value
Quality Score
45
Growth Score
39
Sentiment Score
71
Actual DrawDown %
85
Max Drawdown 5-Year %
Target Price
6
P/E
Forward P/E
PEG
P/S
2.76
P/B
1.63
P/Free Cash Flow
EPS
-0.52
Average EPS Est. Cur. Y
-0.09
EPS Next Y. (Est.)
0.05
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-33.02
Relative Volume
0.66
Return on Equity vs Sector %
-46.8
Return on Equity vs Industry %
-31.3
EPS 1 7Days Diff
-0.1
EPS 1 30Days Diff
-0.07
EBIT Estimation
◆
CTKB
Healthcare
$4.32
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
45.2
Range 1M
46.4%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
59.6%
EPS NY
31.4%
52W%
51.2%
Long-Term Value
Quality companies, undervalued
WEAK
🔴 SELL
-31.4% upside
Upside
-31.4%
Quality
45
Cytek Biosciences, Inc.Sector: Healthcare
Industry: Medical Devices
Employees: 702
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lights systems, and Cytek aurora evo systems delivers cell analysis; Cytek Aurora CS System, a cellular complexity to perform additional downstream genomic and proteomic studies using phenotyping approaches; enhanced small particle detection; Cytek amnis imagestream imaging flow cytometers; Cytek guava muse cell analyzers; Cytek muse micro cell analyzers; Cytek guava easyCyte flow cytometers; and Cytek orion reagent cocktail preparation systems. It also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments. In addition, the company offers automated micro-sampling system and automated sample loader system, an automated loaders designed to integrate seamlessly into the Cytek aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for Cytek aurora, northern lights, and Cytek aurora evo systems; and customer support tools. Further, it provides conventional flow and image-based flow cytometry instrumentation and related products and services under the Amnis and Guava brand names. The company serves pharmaceutical and biopharma companies, academic research centers, and contract research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in Europe, Latin America, and the Middle East countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
CTKB
Latest News
—
Caricamento notizie per CTKB…
stock quote shares CTKB – Cytek Biosciences, Inc. Stock Price stock today
news today CTKB – Cytek Biosciences, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch CTKB – Cytek Biosciences, Inc. yahoo finance google finance
stock history CTKB – Cytek Biosciences, Inc. invest stock market
stock prices CTKB premarket after hours
ticker CTKB fair value insiders trading